Swiss ADC specialist ADC Therapeutics has reported a statistically positive Phase III result for Zynlonta in relapsed or refractory diffuse large B-cell lymphoma, but a higher rate of fatal adverse events in the experimental arm has overshadowed the efficacy readout and triggered a sharp investor backlash.
The announcements came almost simultaneously and send a clear signal to policymakers and the industry: both US pharmaceutical group Eli Lilly and German-based Boehringer Ingelheim are calling planned investments in Germany into question, citing the country’s healthcare policy framework.
Barcelona-based Ona Therapeutics has raised US$86.6m in a Series B financing to advance a new generation of antibody-drug conjugates into clinical development.
Warsaw-based AI biology company Ingenix has raised €13m in a seed-extension financing round led by Sofinnova Partners, with participation from Inovo VC and OTB VC.
London-based IMU Biosciences has expanded its Series A financing to more than US$53m (£40m/€46m) in an oversubscribed round, as the company looks to scale its immune-profiling platform and move further into clinical applications.
Parisian Abivax shared positive topline results for its Phase 3 trial in ulcerative colitis. Its investigational oral, first-in-class miR-124 enhancer, dubbed obefazimod, met all primary and secondary endpoints, yet investors reacted negatively.
A restart from within: Molecular Health is becoming Lucera. After years of shifting corporate fortunes, a substantial part of Heidelberg-based Molecular Health is continuing in a new form. An investor consortium has acquired the company’s pharma technology business and relaunched it as Lucera GmbH. Dr Friedrich von Bohlen remains at the helm, while Dr Stephan Brock, the mind behind the Dataome data engine, also stays on board as CTO.
Oxford-based Greywolf Therapeutics has reported early clinical activity for its first-in-class oral ERAP1 inhibitor GRWD5769 in combination with the anti-PD-1 antibody cemiplimab across six solid tumour types, presenting Phase 1b data from the EMITT-1 trial at the 2026 ASCO Annual Meeting.
Immatics has published a series of updates on its PRAME pipeline, using the American Society for Clinical Oncology (ASCO) Annual Meeting to share data on its lead candidate and next-generation program.
Swiss ophthalmology biotech Oculis has suffered a major setback for its most advanced ophthalmology programme after two pivotal Phase III trials of OCS-01 eye drops in diabetic macular edema failed to meet their primary endpoint.
Elnur Amikishiyev-stock.adobe.com